Arrotex Pharmaceuticals
Arrotex Pharmaceuticals is Australia's largest pharmaceutical provider, supplying 350+ prescription medicines and 1,298 SKUs to pharmacies and hospitals, fulfilling 1 in 2 PBS scripts, and licensing innovative medicines from 24+ multinational partners across Australia and New Zealand.
- Company typePrivate
- Founded2019
- HeadquartersMelbourne, Australia
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Arrotex Pharmaceuticals does
Arrotex Pharmaceuticals is Australia's largest and most diversified pharmaceutical provider, operating as a subsidiary of Australian-owned conglomerate DBG Health. The company supplies more than 350 prescription medicines across 1,298 SKUs to community pharmacies, public and private hospitals, and licensing partners across Australia and New Zealand, fulfilling approximately 1 in every 2 PBS (Pharmaceutical Benefits Scheme) scripts and representing an estimated 50% of Australia's total pharmaceutical volume. Its core product lines span generic medicines, branded prescription medicines, hospital medicines, biologics and biosimilars (including first-to-market launches with Celltrion), and innovative medicines licensed from multinational pharmaceutical partners such as CStone Pharmaceuticals, LENZ Therapeutics, George Medicines, Formosa Pharmaceuticals, Dong-A ST, Antengene, and Juniper Biologics.
Arrotex monetizes through a hybrid model: one-time and volume-based distribution of generics and biosimilars under the PBS framework, licensing royalties and milestone payments from multinational partners whose branded and innovative medicines it commercializes, and upfront plus gross-margin-share economics on exclusive licensing deals (24+ partnerships disclosed). Customer segments include patients (across cardiometabolic, oncology, ophthalmology, and musculoskeletal therapeutic areas), community pharmacies, public and private hospitals, and multinational pharmaceutical companies seeking an Australian commercialization partner. Adjacent operations include Arrovet (animal health) and VidaCorp (consumer health and beauty, housing PONi Cosmetics, esmi Skin Minerals, Lip Heroes, and Sun Skills), the latter created through the 2024 acquisition of Makeup Cartel from Point King Capital.
The company's go-to-market relies on its unmatched pharmacist and prescriber access, regulatory expertise across Australia's TGA and New Zealand's Medsafe, and an 8-office international footprint spanning Melbourne, Sydney, Auckland, New York, London, Amsterdam, and Singapore. Arrotex is ranked #1 in Australia for new product launches and operates the SupportEd patient support program with more than 320,000 enrolled patients. The business is privately held with no public listing, no disclosed funding rounds, and ownership consolidated under DBG Health.
Arrotex Pharmaceuticals firmographics
Firmographics- Name
- Arrotex Pharmaceuticals
- Legal name
- DBG Health
- Website
- https://arrotex.com.au
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Arrotex Pharmaceuticals is Australia's largest pharmaceutical provider, supplying 350+ prescription medicines and 1,298 SKUs to pharmacies and hospitals, fulfilling 1 in 2 PBS scripts, and licensing innovative medicines from 24+ multinational partners across Australia and New Zealand.
- Ownership category
- akta.pro rank
Arrotex Pharmaceuticals industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Full-Line Pharmaceutical Wholesalers (HLAIAJAA)
- akta.pro secondary industries
- Specialty Care Pharmaceuticals (HLAIAAAB), Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)
Keywords
Where Arrotex Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices9 records
Markets served
Arrotex Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure, Technology or R&D
Revenue model
- Generic Medicines: Arrotex provides branded and generic prescription medicines across the spectrum of therapeutic areas, fulfilling 1 in every 2 PBS (Pharmaceutical Benefits Scheme) scripts in Australia. This forms the core revenue base.
- Branded Medicines: Arrotex serves as the Australian partner of choice for multinational pharmaceutical companies, representing and commercializing branded medicines. Over 15 years of proven success in representing branded medicines.
- Innovative Medicines Licensing: Arrotex grants exclusive licenses to international pharma partners to commercialize their innovative medicines in Australia and New Zealand, receiving upfront payments, milestone payments, and royalties on sales.
- Hospital Medicines: Arrotex is Australia's leading provider of hospital medicines, supplying a broad portfolio to public and private hospitals with robust supply infrastructure.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Arrotex Pharmaceuticals product offering
Product offeringCore offering
Arrotex Pharmaceuticals manufactures, supplies, and commercializes generic, branded, hospital, biologic, and biosimilar prescription medicines across Australia and New Zealand through a portfolio of more than 350 prescription medicines and 1,298+ SKUs. The company serves as the Australian commercialization partner of choice for multinational pharmaceutical companies via exclusive licensing deals (sugemalimab, VIZZ, GMRx2, APP13007, and others), and fulfils 1 in every 2 PBS scripts nationally. It also operates adjacent consumer health (VidaCorp) and animal health (Arrovet) businesses.
Product overview
Arrotex Pharmaceuticals is Australia's largest and most diversified pharmaceutical provider offering a platform of prescription medicines across multiple segments: (1) Generic Medicines - the core offering fulfilling 1 in 2 PBS scripts with 1,298 prescription SKUs; (2) Branded Medicines - representing multinational pharmaceutical brands; (3) Innovative Medicines - licensing partnerships for novel therapies; (4) Hospital Medicines - leading provider to public and private hospitals; and (5) Biologics and Biosimilars - including first-to-market biosimilars with Celltrion. The company also operates consumer health through VidaCorp (acquired beauty brands PONi Cosmetics, esmi Skin Minerals, Lip Heroes, Sun Skills) and animal health through ArroVet. Licensed products include sugemalimab (CStone), VIZZ (LENZ), GMRx2 (George Medicines), and APP13007 (Formosa Pharmaceuticals). The company maintains 24+ multinational partnerships and operates across Australia, New Zealand, and international offices.
Differentiator
Problem solved
Functional benefit
Brands
- VidaCorp: Consumer health and beauty enterprise created from the Makeup Cartel acquisition
- Arrovet
- PONi Cosmetics
- esmi Skin Minerals
- Lip Heroes
- Sun Skills
Products and services
- Generic Medicines Arrotex offers the most extensive range of prescription generic medicines across therapeutic areas, fulfilling 1 in every 2 PBS scripts in Australia with 1,298+ prescription SKUs, supplied to community pharmacies and hospitals.
- Branded Medicines Arrotex represents and commercializes branded medicines for multinational pharmaceutical companies in Australia, acting as the strategic partner of choice to grow and protect their brands in the Australian market.
- Innovative Medicines (Licensing Partnerships) Exclusive licensing and commercialization partnerships providing Australian patients access to innovative medicines from international pharma companies, leveraging Arrotex's TGA/Medsafe regulatory expertise and distribution platform.
- Hospital Medicines Broad portfolio and range of presentations of hospital medicines supplied to public and private hospitals across Australia, supported by robust supply infrastructure and innovative solutions.
- Biologics and Biosimilars Largest biologics and biosimilars range in Australia, including first-to-market biosimilars launched in partnership with Celltrion, supplied to pharmacies and hospitals.
- SupportEd Patient Support Program Integrated patient support program providing therapy support to patients enrolled across Arrotex's prescription medicines portfolio, with more than 320,000 patients enrolled.
- OraDerm Dermatology brand represented and commercialized by Arrotex in Australia.
- Sugemalimab (Australia and New Zealand) Anti-PD-L1 antibody from CStone Pharmaceuticals, licensed to Arrotex for exclusive commercialization across approved and future indications in Australia and New Zealand.
- VIZZ (Aceclidine Ophthalmic Solution) FDA-approved aceclidine ophthalmic solution for presbyopia treatment from LENZ Therapeutics, licensed to Arrotex for exclusive commercialization in Australia and New Zealand.
- GMRx2 (Triple-combination Hypertension Treatment) Single-pill triple-combination hypertension treatment from George Medicines, licensed to Arrotex for exclusive commercialization in Australia and New Zealand, addressing hypertension affecting approximately 1 in 3 adults in both countries.
- APP13007 (Clobetasol Propionate Ophthalmic Suspension) FDA-approved clobetasol propionate ophthalmic suspension from Formosa Pharmaceuticals for treatment of inflammation and pain following ocular surgery, licensed to Arrotex for exclusive commercialization in Australia and New Zealand, representing approximately 250,000 cataract surgeries annually in the territory.
- Arrovet (Animal Health) Animal health business under DBG Health, providing veterinary pharmaceutical products and services.
Quantifiable outcome
- 1 in every 2 PBS scripts in Australia fulfilled by Arrotex
- +3 more outcomes
Companies that use Arrotex Pharmaceuticals
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Arrotex Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Arrotex Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core.
- CStone PharmaceuticalscoreCStone Pharmaceuticals entered an exclusive commercialization agreement with Arrotex for sugemalimab in Australia and New Zealand. CStone will receive an upfront payment plus regulatory and commercial milestone payments, while supplying the drug and sharing profits. This is sugemalimab's fifth international partnership, extending its global footprint to over 60 countries across Europe, Middle East and Africa, Latin America, and Oceania.
- LENZ TherapeuticscoreLENZ Therapeutics granted Arrotex exclusive licensing and commercialization rights for VIZZ (aceclidine ophthalmic solution), an FDA-approved presbyopia eye drop therapy, in Australia and New Zealand. LENZ receives an upfront payment plus a share of gross margin from product sales. This is LENZ's fifth ex-US commercialization partnership for VIZZ, which received FDA approval in July 2025 and has been commercially available in the United States since October 2025.
- George MedicinescoreGeorge Medicines entered an exclusive licensing and supply agreement granting Arrotex exclusive rights to commercialize GMRx2, its single-pill triple-combination hypertension treatment, in Australia and New Zealand. George Medicines will receive an upfront licensing fee, commercial milestone payments, and tiered royalties on future sales. Arrotex will seek regulatory approval from Australia's TGA and New Zealand's Medsafe.
- Formosa PharmaceuticalscoreTaiwan-based Formosa Pharmaceuticals entered an exclusive licensing agreement with Arrotex for commercialization of its FDA-approved clobetasol propionate ophthalmic suspension (APP13007) in Australia and New Zealand, covering treatment of inflammation and pain following ocular surgery. The deal includes upfront payments, regulatory milestones, sales milestones, and royalty considerations, with the territory representing approximately 250,000 cataract surgeries annually.
- Dong-A STcoreArrotex signed an exclusive licensing agreement with Korea-based Dong-A ST for innovative medicines. This partnership is highlighted as a news item on the Arrotex website under the 'Innovative Medicines' section.
- AntengenecoreArrotex partnered with Antengene on a therapy for multiple myeloma. This partnership was highlighted in the news section of the Arrotex website.
- CelltrioncoreArrotex and Celltrion launched two first-to-market biosimilars. This partnership was highlighted in the news section as a key biosimilar initiative.
- Juniper BiologicscoreArrotex entered an exclusive partnership with Juniper Biologics, highlighted as a strategic growth initiative in the news section.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Arrotex Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Sigma Healthcare: Australia's largest full-line pharmaceutical distributor, wholesaling PBS-listed medicines to community pharmacies and hospitals — directly comparable to Arrotex on product breadth, customer base, and PBS volume exposure.
- Australian Pharmaceutical Industries (Wesfarmers Health): Leading Australian pharmaceutical distributor and pharmacy services operator (acquired by Wesfarmers in 2021), serving community pharmacies with branded, generic, and OTC medicines — overlapping customer base and distribution model with Arrotex.
- EBOS Group: Trans-Tasman healthcare distributor operating across Australia and New Zealand, supplying prescription medicines, consumer health, and animal health products — comparable to Arrotex's AU/NZ dual-market presence and product breadth.
- Clifford Hallam Healthcare (CHH): Australian pharmaceutical and consumer health wholesaler distributing to community pharmacies and hospitals — directly comparable to Arrotex's branded/generic wholesale model.
- Mayne Pharma: Australian specialty and generic pharmaceutical company offering branded generics, women's health, and dermatology products — comparable to Arrotex's branded generics portfolio and specialty care focus.
Broad incumbents
- CSL Limited: Australia's largest biopharmaceutical company focused on plasma-derived therapies and vaccines — overlapping Australian pharma footprint but specialized in plasma/biologics rather than Arrotex's distribution-led model.
- Aspen Pharmacare: Global specialty and generic pharmaceutical manufacturer/distributor with operations across emerging and developed markets — comparable branded-generic-distribution model but with broader geographic and therapeutic scope than Arrotex.
- Apotex: Canadian generic pharmaceutical manufacturer with global operations producing prescription generics and biosimilars — comparable to Arrotex's generic manufacturing and supply footprint though heavier on manufacturing than distribution.
- Sandoz Group: Global leader in generics and biosimilars (spun out of Novartis) — provides large-scale pharmaceutical supply and biosimilars competitive overlap with Arrotex's Celltrion-partnered biosimilar franchise.
- Mundipharma: Multinational pharmaceutical company with established Asia-Pacific presence marketing branded specialty medicines — comparable business model of representing licensed/marketed brands in regional markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Arrotex Pharmaceuticals social profiles
Digital presenceArrotex Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arrotex Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles1 record
Arrotex Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries3 records
Arrotex Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arrotex Pharmaceuticals M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arrotex Pharmaceuticals
What does Arrotex Pharmaceuticals do?
Arrotex Pharmaceuticals manufactures, supplies, and commercializes generic, branded, hospital, biologic, and biosimilar prescription medicines across Australia and New Zealand through a portfolio of more than 350 prescription medicines and 1,298+ SKUs. The company serves as the Australian commercialization partner of choice for multinational pharmaceutical companies via exclusive licensing deals (sugemalimab, VIZZ, GMRx2, APP13007, and others), and fulfils 1 in every 2 PBS scripts nationally. It also operates adjacent consumer health (VidaCorp) and animal health (Arrovet) businesses.
Is Arrotex Pharmaceuticals a public or private company?
Arrotex Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was Arrotex Pharmaceuticals founded?
Arrotex Pharmaceuticals was founded in 2019. It employs 251 to 500 people.
Where is Arrotex Pharmaceuticals based?
Arrotex Pharmaceuticals is headquartered in Melbourne, Australia, in the Oceania region.
How does Arrotex Pharmaceuticals make money?
Four revenue lines are on record. Generic Medicines are the primary driver. The others are branded Medicines, innovative Medicines Licensing and hospital Medicines.
Who are Arrotex Pharmaceuticals's main competitors?
Direct peers on record are Sigma Healthcare, Australian Pharmaceutical Industries (Wesfarmers Health), EBOS Group, Clifford Hallam Healthcare (CHH) and Mayne Pharma. Broad incumbents are CSL Limited, Aspen Pharmacare, Apotex, Sandoz Group and Mundipharma.
Does Arrotex Pharmaceuticals have an API?
No public API is recorded for Arrotex Pharmaceuticals.
What industry is Arrotex Pharmaceuticals in?
Arrotex Pharmaceuticals's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAJAA, Full-Line Pharmaceutical Wholesalers, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 5122.